Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Clinical trial NCT05478343 · UNKNOWN

Trial details

NCT number: NCT05478343
Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2021-05-06
Primary completion: 2023-05-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.